Devices descending from K063597
20 later devices reach Vitek 2 Gram Positive Amoxicillin for Streptococcus Pneumoniae through their predicates, nearest generation first.
| Generation | Number | Device | Applicant | Decided | Own descendants | Recalls |
|---|---|---|---|---|---|---|
| +1 | K121100 | Vitek 2 Ast Streptococus Vancomycin | bioMerieux, Inc. | 2012 | 0 | 1 |
| +1 | K122359 | Vitek 2 Strptococcus Ceftriaxone | bioMerieux, Inc. | 2012 | 1 | — |
| +1 | K121863 | Vitek 2 Ast-ST Cefotaxime | bioMerieux, Inc. | 2012 | 2 | — |
| +1 | K113783 | Vitek 2 Ast- Gram Postive Penicillin for Streptococcus Pneumoniae | bioMerieux, Inc. | 2012 | 0 | — |
| +1 | K111893 | Vitek (R) 2 Streptococcus Tetracycline | bioMerieux, Inc. | 2012 | 1 | — |
| +1 | K111976 | Vitek 2 Streptococcus Erythromycin | bioMerieux, Inc. | 2012 | 0 | — |
| +1 | K113305 | Vitek 2 Streptococcus Trimethoprim/Sulfamethoxazole | bioMerieux, Inc. | 2012 | 0 | — |
| +1 | K112000 | Vitek 2 Streptococcus Penicillin | bioMerieux, Inc. | 2011 | 3 | — |
| +1 | K112228 | Vitek 2 Streptococcus Levofloxacin | bioMerieux, Inc. | 2011 | 0 | — |
| +1 | K112129 | Vitek (R) 2 Streptococcus Clindamycin | bioMerieux, Inc. | 2011 | 0 | — |
| +1 | K112075 | Vitek 2 Strptococcus Ampicillin | bioMerieux, Inc. | 2011 | 0 | — |
| +1 | K111599 | Vitek 2 Ast-ST Linezolid | bioMerieux, Inc. | 2011 | 1 | — |
| +2 | K232201 | VITEK 2 AST-Streptococcus Penicillin (<=0.06 - =>8 µg/mL), VITEK 2 Streptococcus… | bioMerieux, Inc. | 2023 | 2 | — |
| +2 | K223481 | VITEK® 2 Streptococcus Tetracycline (<=0.25 - >=16 µg/mL) | bioMerieux, Inc. | 2023 | 0 | — |
| +2 | K210287 | VITEK 2 AST- Streptococcus Cefotaxime (<=0.125 - =>8 ug/mL) | bioMerieux, Inc. | 2021 | 0 | — |
| +2 | K132507 | Vitek 2 Ast ST Meropenem | bioMerieux, Inc. | 2013 | 0 | — |
| +2 | K131779 | Vitek 2 Ast-ST Tigecycline | bioMerieux, Inc. | 2013 | 0 | — |
| +2 | K132573 | Vitek 2 Ast ST Moxifloxacin, Vitek 2 Ast Streptococcus Moxifloxacin | bioMerieux, Inc. | 2013 | 0 | — |
| +3 | K260619 | VITEK 2 AST-Streptococcus Cefepime (<=0.06 – >=4 µg/mL) | Biomérieux, Inc. | 2026 | 0 | — |
| +3 | K260281 | VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL) | Biomerieux | 2026 | 0 | — |